Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update

Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 21,000,000 shares, an increase of 5.5% from the October 31st total of 19,900,000 shares. Based on an average daily trading volume, of 2,380,000 shares, the short-interest ratio is currently 8.8 days.

Analyst Ratings Changes

A number of analysts have weighed in on FOLD shares. Morgan Stanley lowered their target price on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. Jefferies Financial Group started coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. Cantor Fitzgerald upped their price target on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $9.86 on Thursday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The stock’s fifty day moving average price is $10.65 and its 200 day moving average price is $10.61. Amicus Therapeutics has a 1 year low of $9.02 and a 1 year high of $14.57. The company has a market cap of $2.95 billion, a price-to-earnings ratio of -29.00 and a beta of 0.60.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 30,401 shares of company stock worth $339,363 over the last 90 days. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Hedge funds have recently made changes to their positions in the company. OLD Second National Bank of Aurora purchased a new stake in Amicus Therapeutics in the third quarter valued at $26,000. Hazlett Burt & Watson Inc. boosted its holdings in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Blue Trust Inc. boosted its holdings in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new stake in Amicus Therapeutics in the third quarter valued at $32,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics in the third quarter valued at $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.